Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans.
The immunogenicity and toxicity of a purified influenza virus (N2) neuraminidase vaccine (NAV) were investigated in 88 human subjects aged 18-40, and compared to response to a conventional trivalent influenza vaccine, Fluogen (Parke-Davis). NAV doses ranged from 2.6 to 69.9 micrograms and were given intramuscularly. Serologic neuraminidase-inhibiting (NI) and neuraminidase-specific ELISA responses in this N2-primed population were roughly proportional to the dose administered. Maximal response was seen in 14-21 days and NI antibody titers persisted unabated for the 6-month post-vaccination follow-up period. All doses were well tolerated with respect to local and systemic reactions. NI tests performed with the putative (1975) priming N2 antigen demonstrated anamnestic response but did not reveal responses not already shown with the homologous (1992) antigen. Response to this purified, non-adjuvanted preparation encourages continuing investigation of the induction of infection-permissive immunity with influenza virus neuraminidase.
Kilbourne
E D
ED
Department of Microbiology and Immunology, New York Medical College, Valhalla 10595, USA.
Couch
R B
RB
Kasel
J A
JA
Keitel
W A
WA
Cate
T R
TR
Quarles
J H
JH
Grajower
B
B
Pokorny
B A
BA
Johansson
B E
BE
D000293:Adolescent; D000328:Adult; D000917:Antibody Formation; D000918:Antibody Specificity; D002846:Chromatography, Affinity; D006801:Humans; D009980:Influenza A virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000009:adverse effects / Q000276:immunology*; D009439:Neuraminidase / Q000276:immunology*
D007252:Influenza Vaccines; D009439:Neuraminidase